Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Open in Screener

ALEC

Alector Inc

Jun 26 • 11:54AM ET

4.34

Dollar change -0.02
Percentage change -0.35	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF XBI IWO IBB SCHA VTWO VHT ESML

Index	RUT	P/E	-	EPS (ttm)	-1.39	Insider Own	21.98%	Shs Outstand	84.88M	Perf Week	1.99%
Market Cap	418.75M	Forward P/E	-	EPS next Y	-1.66	Insider Trans	-0.44%	Shs Float	75.20M	Perf Month	-12.93%
Income	-120.61M	PEG	-	EPS next Q	-0.50	Inst Own	75.51%	Short Float	11.40%	Perf Quarter	-27.10%
Sales	96.41M	P/S	4.34	EPS this Y	-26.38%	Inst Trans	0.70%	Short Ratio	13.59	Perf Half Y	-45.76%
Book/sh	1.86	P/B	2.34	EPS next Y	15.69%	ROA	-17.43%	Short Interest	8.57M	Perf Year	-28.72%
Cash/sh	5.83	P/C	0.75	EPS next 5Y	-10.70%	ROE	-66.65%	52W Range	3.66 - 9.06	Perf YTD	-45.55%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.76%	ROI	-58.01%	52W High	-52.07%	Beta	0.72
Dividend TTM	-	Quick Ratio	3.53	Sales past 5Y	158.96%	Gross Margin	90.63%	52W Low	18.71%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	3.53	EPS Y/Y TTM	14.46%	Oper. Margin	-150.75%	RSI (14)	40.08	Volatility	7.71% 6.43%
Employees	244	Debt/Eq	0.21	Sales Y/Y TTM	-23.30%	Profit Margin	-125.11%	Recom	1.90	Target Price	13.75
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	30.30%	Payout	-	Rel Volume	0.61	Prev Close	4.36
Sales Surprise	6.98%	EPS Surprise	25.21%	Sales Q/Q	-3.96%	Earnings	May 08 AMC	Avg Volume	630.59K	Price	4.34
SMA20	-6.55%	SMA50	-13.59%	SMA200	-26.63%	Trades		Volume	154,124	Change	-0.35%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Upgrade	Stifel	Hold → Buy	$8 → $15
Dec-12-23	Initiated	Deutsche Bank	Buy	$12
Sep-25-23	Initiated	Goldman	Sell	$4
Sep-22-23	Initiated	Cantor Fitzgerald	Overweight	$13
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral	$24 → $12
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27 → $13
Jul-07-22	Initiated	Mizuho	Buy	$15
Apr-13-22	Initiated	Goldman	Sell	$9
Mar-08-22	Downgrade	Stifel	Buy → Hold	$32 → $18
Sep-27-21	Initiated	William Blair	Outperform
Jan-15-21	Resumed	BofA Securities	Buy	$35
Jun-24-20	Initiated	H.C. Wainwright	Buy	$41
Apr-28-20	Initiated	Goldman	Buy	$32
Mar-06-20	Initiated	Citigroup	Buy	$40
Feb-27-20	Initiated	Barclays	Overweight	$36
Feb-19-20	Initiated	Stifel	Buy	$44
Nov-21-19	Initiated	BTIG Research	Buy	$28
Mar-04-19	Initiated	SVB Leerink	Outperform
Mar-04-19	Initiated	Morgan Stanley	Overweight	$27
Mar-04-19	Initiated	BofA/Merrill	Buy	$26

Show Previous Ratings

Jun-20-24 07:00AM	Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-10-24 07:00AM	Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform (GlobeNewswire)
Jun-03-24 07:00AM	Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-09-24 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
May-08-24 11:55PM	ALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:25PM	Loading…
06:25PM	Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:19PM	Alector: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-25-24 10:02AM	Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know (Zacks) -8.38%
Feb-28-24 02:02PM	Q4 2023 Alector Inc Earnings Call (Thomson Reuters StreetEvents)
10:13AM	Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Feb-27-24 04:46PM	Alector Inc (ALEC) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com) +8.18%
04:23PM	Alector: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
04:05PM	Loading…
Feb-20-24 04:05PM	Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call (GlobeNewswire)
10:00AM	Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline (Zacks)
Feb-08-24 07:00AM	Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease (GlobeNewswire)
06:48AM	Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength? (Zacks)
Feb-07-24 07:00AM	FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) (GlobeNewswire) +5.96%
Jan-25-24 12:00PM	Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-23-24 07:32AM	Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs (InvestorPlace)
Jan-19-24 09:20AM	Alector Announces Closing of Public Offering (GlobeNewswire)
Jan-17-24 08:54AM	Alector Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -14.01%
Jan-16-24 04:01PM	Alector Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-08-24 01:25PM	Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 (Investor's Business Daily) +7.34%
Dec-05-23 09:55AM	Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet (Zacks)
Nov-28-23 07:00AM	Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs (GlobeNewswire)
Nov-14-23 09:35AM	Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +14.06%
Nov-08-23 07:00AM	Alector to Participate in the Stifel Healthcare Conference (GlobeNewswire) -7.30%
06:02PM	Loading…
Nov-07-23 06:02PM	Alector: Q3 Earnings Snapshot (Associated Press Finance) +5.12%
05:11PM	Alector Inc (ALEC) Reports Q3 2023 Financial Results with Key Clinical Advancements (GuruFocus.com)
04:05PM	Alector Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-23 07:00AM	Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) (GlobeNewswire)
Sep-14-23 01:12AM	10% Owner Polaris Venture Management Co. VI, L.L.C. Sells 500,000 Shares of Alector Inc (GuruFocus.com)
Sep-08-23 12:10PM	Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study (Zacks)
Sep-07-23 07:00AM	Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimers Disease (GlobeNewswire) +6.76%
Aug-31-23 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-10-23 09:55AM	Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade (Zacks)
Aug-03-23 05:45PM	Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates (Zacks) +32.38%
04:43PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-27-23 08:30AM	Alector to Host Mid-Year Earnings Conference Call (GlobeNewswire)
Jul-13-23 01:29PM	7 Stocks That AI Says Will Make You a Millionaire by 2025 (InvestorPlace)
Jun-06-23 07:00AM	Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-01-23 07:29AM	Companies Like Alector (NASDAQ:ALEC) Are In A Position To Invest In Growth (Simply Wall St.) -8.20%
May-09-23 09:55AM	Does Alector (ALEC) Have the Potential to Rally 86.38% as Wall Street Analysts Expect? (Zacks)
May-05-23 06:31AM	Benign Growth For Alector, Inc. (NASDAQ:ALEC) Underpins Its Share Price (Simply Wall St.) +10.27%
May-04-23 07:35PM	Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:27PM	Alector: Q1 Earnings Snapshot (AP Finance)
04:05PM	Alector Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-02-23 07:00AM	Alector to Participate in the BofA Securities 2023 Healthcare Conference (GlobeNewswire)
May-01-23 10:01AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-27-23 10:03AM	Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-13-23 12:59PM	Shareholders in Alector (NASDAQ:ALEC) are in the red if they invested three years ago (Simply Wall St.)
08:30AM	Are Options Traders Betting on a Big Move in Alector (ALEC) Stock? (Zacks)
Mar-01-23 04:05PM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire) -6.36%
Feb-28-23 04:05PM	Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-20-23 10:00AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-17-23 06:01AM	Alector, Inc. (NASDAQ:ALEC) is a favorite amongst institutional investors who own 64% (Simply Wall St.)
Feb-16-23 10:01AM	Alector (ALEC) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Dec-21-22 05:01AM	We're Not Very Worried About Alector's (NASDAQ:ALEC) Cash Burn Rate (Simply Wall St.)
Dec-08-22 04:30PM	Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-29-22 11:05AM	Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases (GlobeNewswire)
Nov-10-22 05:13AM	Alector Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) +19.62%
Nov-08-22 07:45PM	Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -19.81%
04:05PM	Alector Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Nov-04-22 11:05AM	Alector (NASDAQ:ALEC) investors are sitting on a loss of 65% if they invested a year ago (Simply Wall St.)
Nov-03-22 04:30PM	Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-13-22 08:00AM	Alector Announces Promotion of Clare Hunt to Chief People Officer (GlobeNewswire)
Oct-06-22 04:30PM	Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-22 07:00AM	Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimers Disease (AD) (GlobeNewswire) +5.66%
Sep-07-22 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire) +8.28%
Aug-09-22 09:55AM	Wall Street Analysts Believe Alector (ALEC) Could Rally 58%: Here's is How to Trade (Zacks)
Aug-06-22 08:33AM	Alector, Inc.'s (NASDAQ:ALEC) Stock Is Going Strong: Have Financials A Role To Play? (Simply Wall St.)
Aug-04-22 07:15PM	Alector (ALEC) Q2 Earnings and Revenues Beat Estimates (Zacks) +15.27%
04:05PM	Alector Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Jul-08-22 10:54AM	AbbVie Dumps An Early-Alzheimer's Candidate Developing In Collaboration With Alector (Benzinga)
Jul-07-22 05:59PM	Alzheimer's drug cut loose from Peninsula biotech's collaboration but another survives (American City Business Journals)
Jun-08-22 07:00AM	Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire)
May-28-22 08:20AM	Shareholders in Alector (NASDAQ:ALEC) are in the red if they invested a year ago (Simply Wall St.)
May-27-22 04:30PM	Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules (GlobeNewswire)
May-05-22 06:25PM	Alector (ALEC) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.67% -6.51%
04:05PM	Alector Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-04-22 07:00AM	Alector to Participate at the BofA Securities 2022 Healthcare Conference (GlobeNewswire)
May-02-22 07:47AM	New Strong Sell Stocks for May 2nd (Zacks)
Apr-27-22 03:03PM	Alector (ALEC) to Report Q1 Results: Wall Street Expects Earnings Growth (Zacks)
Mar-29-22 04:05PM	Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Mar-15-22 12:04PM	Alector Highlights Mid-Stage Study Data On Lead Dementia Drug (Benzinga)
08:00AM	Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial (GlobeNewswire)
Mar-09-22 07:00AM	Alector to Present at Upcoming Healthcare Conferences (GlobeNewswire) +12.45%
Mar-08-22 07:00AM	Alector to Present New AL001 Data at AD/PD 2022 (GlobeNewswire) -9.70%
Mar-01-22 04:30PM	Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules (GlobeNewswire)
04:05PM	Alector to Participate at the Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Feb-24-22 06:50PM	Alector (ALEC) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Alector Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-17-22 03:02PM	Will Alector (ALEC) Report Negative Q4 Earnings? What You Should Know (Zacks)
Feb-14-22 04:30AM	International Petroleum Corporation Announces Results of Share Repurchase Program (GlobeNewswire)
Feb-07-22 08:30AM	Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer (GlobeNewswire)

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rosenthal Arnon	Chief Executive Officer	Jun 03 '24	Sale	4.80	25,135	120,618	1,975,245	Jun 04 06:05 PM
Kenkare-Mitra Sara	President and Head of R&D	Jun 03 '24	Sale	4.80	13,206	63,373	305,641	Jun 04 06:05 PM
Romano Gary	Chief Medical Officer	Jun 03 '24	Sale	4.80	8,040	38,582	188,273	Jun 04 06:05 PM
GRASSO MARC	Chief Financial Officer	Jun 03 '24	Sale	4.80	6,920	33,208	138,037	Jun 04 06:05 PM
Rosenthal Arnon	Chief Executive Officer	Mar 04 '24	Sale	6.92	18,837	130,386	2,000,380	Mar 05 06:00 PM
Kenkare-Mitra Sara	President and Head of R&D	Mar 04 '24	Sale	6.92	10,169	70,387	318,847	Mar 05 06:00 PM
Romano Gary	Chief Medical Officer	Mar 04 '24	Sale	6.92	6,001	41,554	196,313	Mar 05 06:00 PM
GRASSO MARC	Chief Financial Officer	Mar 04 '24	Sale	6.92	5,716	39,562	144,957	Mar 05 06:00 PM
Rosenthal Arnon	Chief Executive Officer	Dec 04 '23	Sale	5.56	23,831	132,500	2,019,217	Dec 06 06:30 PM
Kenkare-Mitra Sara	President and Head of R&D	Dec 04 '23	Sale	5.56	12,519	69,606	329,016	Dec 06 06:30 PM
Romano Gary	Chief Medical Officer	Dec 04 '23	Sale	5.56	5,035	27,995	202,314	Dec 06 06:30 PM
GRASSO MARC	Chief Financial Officer	Dec 04 '23	Sale	5.56	4,574	25,431	150,673	Dec 06 06:30 PM
Polaris Venture Management Co.	10% Owner	Sep 11 '23	Sale	6.00	500,000	3,000,000	10,853,817	Sep 13 04:33 PM
MCGUIRE TERRANCE	Director	Sep 11 '23	Sale	6.00	500,000	3,000,000	10,853,817	Sep 13 04:29 PM
Kenkare-Mitra Sara	President and Head of R&D	Sep 05 '23	Sale	5.19	6,214	32,277	177,935	Sep 06 07:17 PM
Rosenthal Arnon	Chief Executive Officer	Sep 05 '23	Sale	5.19	5,647	29,333	1,645,448	Sep 06 07:18 PM
Romano Gary	Chief Medical Officer	Sep 05 '23	Sale	5.19	2,771	14,393	99,349	Sep 06 07:16 PM
GRASSO MARC	Chief Financial Officer	Sep 05 '23	Sale	5.19	1,114	5,786	32,247	Sep 06 07:14 PM

Open in Screener

CYCN

Cyclerion Therapeutics Inc

Jun 26 • 11:45AM ET

2.30

Dollar change -0.42
Percentage change -15.44	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

CYCN Cyclerion Therapeutics Inc daily Stock Chart

Held by: VXF ONEQ

Index	-	P/E	-	EPS (ttm)	-6.50	Insider Own	23.24%	Shs Outstand	2.47M	Perf Week	4.08%
Market Cap	6.23M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.08M	Perf Month	-17.80%
Income	-15.60M	PEG	-	EPS next Q	-	Inst Own	39.50%	Short Float	0.86%	Perf Quarter	-23.59%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	21.11%	Short Ratio	4.63	Perf Half Y	-2.84%
Book/sh	3.97	P/B	0.58	EPS next Y	-	ROA	-116.78%	Short Interest	0.02M	Perf Year	-47.12%
Cash/sh	2.10	P/C	1.09	EPS next 5Y	-	ROE	-192.45%	52W Range	1.75 - 5.25	Perf YTD	-31.34%
Dividend Est.	-	P/FCF	-	EPS past 5Y	36.06%	ROI	-157.24%	52W High	-56.19%	Beta	1.94
Dividend TTM	-	Quick Ratio	4.17	Sales past 5Y	-33.97%	Gross Margin	-	52W Low	31.43%	ATR (14)	0.40
Dividend Ex-Date	-	Current Ratio	4.17	EPS Y/Y TTM	62.87%	Oper. Margin	0.00%	RSI (14)	43.46	Volatility	31.37% 12.14%
Employees	1	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	80.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	80.65%	Payout	-	Rel Volume	10.49	Prev Close	2.72
Sales Surprise	-13.92%	EPS Surprise	-3.33%	Sales Q/Q	-	Earnings	-	Avg Volume	3.85K	Price	2.30
SMA20	-11.67%	SMA50	-19.84%	SMA200	-25.61%	Trades		Volume	15,901	Change	-15.44%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-21	Initiated	Truist	Buy	$14
Sep-24-21	Initiated	Cantor Fitzgerald	Overweight	$7
Jun-03-19	Initiated	Credit Suisse	Neutral

Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +17.98%
May-08-24 08:52AM	CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024 (InvestorPlace)
Apr-05-24 06:53AM	CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023 (InvestorPlace)
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Dec-04-23 08:00AM	Cyclerion Appoints Regina Graul, Ph.D., as President (GlobeNewswire) -8.71%
06:16PM	Loading…
Nov-30-23 06:16PM	Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator (GlobeNewswire) +7.39% +14.06%
Aug-02-23 08:39PM	The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion assets (American City Business Journals)
Jul-31-23 07:00AM	Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets (GlobeNewswire) +14.15%
Jun-01-23 04:00PM	Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
May-15-23 01:00PM	Cyclerion Announces Reverse Stock Split (GlobeNewswire) -14.34%
May-12-23 02:59PM	Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors (Benzinga) -25.10%
May-11-23 06:00PM	Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 (GlobeNewswire)
06:00PM	Cyclerion Announces Corporate Updates and Q1 2023 Financial Results (GlobeNewswire)
Apr-03-23 07:30AM	Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement (GlobeNewswire) -17.98%
Mar-27-23 07:00AM	Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases (GlobeNewswire) +23.71%
04:40PM	Loading…
Mar-22-23 04:40PM	Cyclerion Reports Corporate Update and Full Year 2022 Financial Results (GlobeNewswire) -11.54%
Nov-22-22 07:00AM	Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company (GlobeNewswire) +34.31%
Nov-09-22 06:34AM	Cyclerion Therapeutics Third Quarter 2022 Earnings: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021) (Simply Wall St.)
Oct-07-22 02:31PM	Cyclerion Therapeutics lays off nearly half of workforce (American City Business Journals) -9.66%
Oct-06-22 12:46PM	Cyclerion Shares Fall After Reprioritized Pipeline, Workforce Reduction (Benzinga) -37.57%
08:00AM	Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy (GlobeNewswire)
Aug-09-22 05:35PM	Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -17.39%
04:00PM	Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-08-22 09:22AM	Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth? (Simply Wall St.) +27.76%
Jul-28-22 07:00AM	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS) (GlobeNewswire) +22.08%
Jul-26-22 07:00AM	Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics Board of Directors (GlobeNewswire)
Jun-28-22 09:00AM	Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation (GlobeNewswire) -5.55%
Jun-22-22 08:30AM	Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation (GlobeNewswire)
Jun-17-22 11:20AM	Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies (Benzinga)
08:00AM	Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease (GlobeNewswire)
07:00AM	Loading…
Jun-10-22 07:00AM	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium (GlobeNewswire) -20.18%
Jun-06-22 07:00AM	Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium (GlobeNewswire) +8.58%
May-11-22 09:30AM	As Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) drops to US$26m market cap, insiders might rethink their US$2.7m stock purchase earlier this year (Simply Wall St.) -8.17%
May-04-22 04:01PM	Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results (GlobeNewswire) +8.62% -5.39%
Feb-27-22 06:39AM	Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-24-22 04:01PM	Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates (GlobeNewswire)
Feb-23-22 08:00AM	Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration (GlobeNewswire)
Feb-01-22 05:30AM	CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board (GlobeNewswire) +9.09%
Jan-26-22 08:00AM	Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimers Disease with Vascular Pathology (GlobeNewswire)
Dec-15-21 10:00AM	Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN) (Zacks) +9.38%
Nov-25-21 04:47AM	Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) insider upped their holding by 67% earlier this year (Simply Wall St.)
Nov-11-21 05:32PM	Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Nov-09-21 04:01PM	Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -5.42%
Nov-08-21 12:00PM	Exclusive: Startup raises $27M to find brain-based biomarkers (American City Business Journals)
Oct-20-21 04:24PM	Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside (Benzinga) +10.90% -5.42%
Oct-11-21 03:34AM	David Greenspans Slate Path Capital is Buying Coinbase, Stitch Fix, and More (Insider Monkey)
Oct-10-21 09:37AM	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions? (Simply Wall St.)
Sep-22-21 08:00AM	Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator (GlobeNewswire)
Sep-08-21 08:00AM	Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-26-21 07:19AM	Cyclerion Therapeutics (NASDAQ:CYCN) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Aug-23-21 05:00PM	Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimers Disease Summit (GlobeNewswire) +8.16%
Jul-29-21 05:00PM	Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -12.54%
Jul-22-21 04:30PM	Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimers Disease with Vascular Pathology at the Alzheimers Association International Conference 2021 (AAIC) (GlobeNewswire) +14.72%
Jul-12-21 02:24AM	Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Are Down 31% On Their Shares (Simply Wall St.)
Jul-09-21 06:14AM	Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers (Benzinga)
Jul-08-21 07:22PM	Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership (PR Newswire)
04:30PM	Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership (GlobeNewswire)
Jun-04-21 10:27AM	Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise (Benzinga)
08:00AM	Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat (GlobeNewswire)
08:00AM	Cyclerion Therapeutics Announces $18 Million Private Placement (GlobeNewswire)
May-27-21 04:30PM	Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology (GlobeNewswire) +5.25%
May-25-21 07:00AM	Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-09-21 03:36AM	The CEO & Director of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), Peter Hecht, Just Bought 309% More Shares (Simply Wall St.)
Apr-27-21 09:00AM	Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress (GlobeNewswire) -17.95%
Apr-26-21 07:00AM	Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors (GlobeNewswire) +7.22%
Apr-21-21 07:30AM	Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference (GlobeNewswire) +5.75%
Apr-20-21 07:00AM	Cyclerion Therapeutics to Host Pipeline Update Webinar (GlobeNewswire) +7.41%
Mar-24-21 04:05PM	TransMedics Appoints Stephanie Lovell to Board of Directors (PR Newswire) -6.80% +5.78%
Mar-22-21 02:23AM	Are Institutions Heavily Invested In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares? (Simply Wall St.)
Mar-19-21 07:46AM	The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs (Benzinga)
Mar-18-21 05:00PM	Cyclerion Therapeutics Announces Departure of Chief Medical Officer (GlobeNewswire)
Feb-25-21 07:00AM	Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update (GlobeNewswire) -9.48%
Jan-25-21 07:00AM	Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards (GlobeNewswire)
Jan-21-21 12:52AM	How Much Did Cyclerion Therapeutics'(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The Last Year? (Simply Wall St.)
Jan-04-21 07:00AM	Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-21-20 07:30AM	Cyclerion Announces Leadership Transitions (GlobeNewswire)
Dec-02-20 11:27PM	Is Cyclerion Therapeutics, Inc. (CYCN) A Good Stock To Buy? (Insider Monkey)
Nov-15-20 07:55AM	Andreas Busch Is The Chief Innovation Officer of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) And They Just Picked Up 96% More Shares (Simply Wall St.)
Nov-05-20 07:00AM	Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates (GlobeNewswire)
Oct-14-20 01:09PM	Why Cyclerion Therapeutics Is Crashing Today (Motley Fool) -52.95%
10:07AM	Cyclerion Sinks As Biopharma Shelves Sickle Cell Disease Study (Benzinga)
07:00AM	Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects (GlobeNewswire)
07:00AM	Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease (GlobeNewswire)
Oct-04-20 09:52AM	Health Check: How Prudently Does Cyclerion Therapeutics (NASDAQ:CYCN) Use Debt? (Simply Wall St.)
Sep-04-20 07:00AM	Cyclerion to Participate at Upcoming September 2020 Investor Conferences (GlobeNewswire)
Aug-25-20 07:00AM	Cyclerion Announces Translational Research Award from the Alzheimers Association Part the Cloud-Gates Partnership Grant Program (GlobeNewswire) +11.09%
Aug-20-20 11:01AM	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions? (Simply Wall St.)
Aug-03-20 09:25AM	Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights (GlobeNewswire) +6.81%
Jul-30-20 09:00AM	Cyclerion Therapeutics Completes $24 Million Private Placement (GlobeNewswire) +12.50%
Jul-17-20 07:00AM	Cyclerion Therapeutics Presentation at Biomarkers in Alzheimers Disease Summit (GlobeNewswire)
Jul-06-20 03:17PM	We're A Little Worried About Cyclerion Therapeutics's (NASDAQ:CYCN) Cash Burn Rate (Simply Wall St.)
Jul-05-20 02:45PM	Should You Buy Cyclerion Therapeutics, Inc. (CYCN)? (Insider Monkey)
Jun-18-20 04:01PM	Cyclerion to Host Webcast Investor Event on July 9, 2020 (GlobeNewswire) +18.04%
May-22-20 07:52AM	The Cyclerion Therapeutics (NASDAQ:CYCN) Share Price Is Down 72% So Some Shareholders Are Rather Upset (Simply Wall St.) +6.45%
Apr-10-20 07:00AM	Cyclerion Updates Corporate Progress (GlobeNewswire)
Mar-23-20 06:50AM	Are Insiders Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Stock? (Simply Wall St.) +18.94%
Jan-13-20 07:00AM	Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases (GlobeNewswire) +10.26%
Jan-12-20 05:05PM	The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO (Benzinga)
Dec-24-19 08:17AM	Can Cyclerion Therapeutics (NASDAQ:CYCN) Afford To Invest In Growth? (Simply Wall St.) +6.87%
Dec-23-19 07:00AM	Cyclerion to Present at the J.P. Morgan Healthcare Conference (GlobeNewswire)

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCGUIRE TERRANCE	Director	Aug 09 '23	Sale	3.40	8	27	0	Aug 11 04:25 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ALEC

Alector Inc

CYCN

Cyclerion Therapeutics Inc

Upgrade your FINVIZ experience